- Report
- October 2024
- 188 Pages
Global
From €3386EUR$3,545USD£2,831GBP
€3762EUR$3,939USD£3,146GBP
- Report
- August 2024
- 100 Pages
Global
From €5682EUR$5,950USD£4,752GBP
- Report
- March 2025
- 94 Pages
Global
From €5348EUR$5,600USD£4,472GBP
- Report
- February 2025
- 200 Pages
Global
From €4288EUR$4,490USD£3,586GBP
- Report
- April 2024
- 135 Pages
Global
From €2864EUR$2,999USD£2,395GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3581EUR$3,750USD£2,995GBP
- Report
- February 2025
- 182 Pages
Global
From €4298EUR$4,500USD£3,594GBP
- Report
- January 2025
- 120 Pages
United States
From €2378EUR$2,490USD£1,989GBP
- Report
- February 2024
- 85 Pages
North America
From €4536EUR$4,750USD£3,794GBP
- Report
- February 2024
- 127 Pages
Global
From €4536EUR$4,750USD£3,794GBP
- Report
- February 2024
- 90 Pages
Europe
From €4536EUR$4,750USD£3,794GBP
- Report
- February 2024
- 120 Pages
Global
From €4536EUR$4,750USD£3,794GBP
- Report
- April 2023
- 80 Pages
Asia Pacific
From €4536EUR$4,750USD£3,794GBP
- Report
- March 2025
- 50 Pages
Global
From €2531EUR$2,650USD£2,116GBP
- Report
- February 2023
- 260 Pages
Global
From €3409EUR$3,570USD£2,851GBP

Ropivacaine is an anesthetic drug used for local and regional anesthesia. It is a local anesthetic of the amide type and is used for infiltration, nerve block, and epidural anesthesia. It is a long-acting anesthetic with a rapid onset and a duration of action of up to three hours. Ropivacaine is used in a variety of medical procedures, including orthopedic, dental, and obstetric procedures. It is also used in the treatment of chronic pain.
Ropivacaine is available in a variety of formulations, including injectable solutions, topical solutions, and transdermal patches. It is also available in combination with other drugs, such as epinephrine and bupivacaine. The safety and efficacy of ropivacaine have been established in clinical trials.
The market for ropivacaine is highly competitive, with several companies offering products. Some of the major players in the market include Hospira, Inc., Baxter International, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., and Fresenius Kabi AG. Show Less Read more